Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

Recent & Breaking News (TSXV:CLAS.H)

Kalytera Therapeutics Announces Filing of Amended and Restated Short Form Prospectus

GlobeNewswire July 26, 2018

Kalytera to make Milestone Payments to Talent Shareholders

Stockhouse Editorial July 20, 2018

Kalytera and Former Shareholders of Talent Biotechs Agree to Deferment of Milestone Payments

GlobeNewswire July 20, 2018

Kalytera Targeting Menstrual Cramps and Psoriasis

Stockhouse Editorial July 19, 2018

Kalytera to Enter Medical Cannabis Market With Focus on Treatment of Psoriasis and Menstrual Cramps

Business Wire July 19, 2018

Kalytera Therapeutics Announces Short Form Prospectus Offering of Units

GlobeNewswire July 10, 2018

Kalytera Announces Pre-IND Meeting Date with FDA

GlobeNewswire July 5, 2018

Kalytera Announces Appointment of Victoria Rudman as Interim Chief Financial Officer and Additional Payments in Shares under Payments Agreements with Salzman Group

GlobeNewswire June 29, 2018

CBD-based drug for juvenile epilepsy receives FDA approval

Market One Media June 28, 2018

Kalytera Provides Update on its Lead Program in Prevention and Treatment of GVHD

GlobeNewswire June 21, 2018

Kalytera Announces Second Payments Agreement with The Salzman Group of Israel

GlobeNewswire June 15, 2018

Kalytera Announces Next Monthly Payment in Shares under Services Agreement with Salzman Group

GlobeNewswire June 4, 2018

Kalytera Reports First Quarter 2018 Financial Results

GlobeNewswire May 30, 2018

Kalytera Forms Advisory Board to Study Pain Treatment

Stockhouse Editorial May 15, 2018

Kalytera Announces Formation of Strategic and Scientific Advisory Board to Assist with Development of Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain

GlobeNewswire May 15, 2018

Kalytera Announces Issuance of Second Patent Covering the Use of CBD in Graft Versus Host Disease

Business Wire May 2, 2018

Kalytera Reports 2017 Financial Results

Business Wire May 1, 2018

Kalytera Announces Next Payment in Shares under Services Agreement with Salzman Group

GlobeNewswire April 20, 2018

Kalytera Announces Issuance of Patent Covering the Use of CBD for the Treatment of Severe and Refractory Graft Versus Host Disease

Business Wire April 19, 2018

Kalytera Terminates Pre-Clinical Programs in Bone Disease

Business Wire April 13, 2018